Shenzhen Chipscreen Biosciences Co., Ltd. (SHENZHEN CHIPSCREEN BIOSCIENCES) aksje

Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research and development of original small molecule drugs. The company develops Chidamide, a subtype-selective histone deacetylase inhibitor for the treatment of peripheral T-cell lymphoma and advanced hormone receptor-positive breast cancer; Chiglitazar Sodium, a PPAR pan-agonist for the treatment of metabolic diseases; and Chiauranib, a triple-pathway tumor-targeting inhibitor. It is also developing CS23546, a small-molecule PD-L1 inhibitor; CS231295, a brain-penetrant Aurora B selective inhibitor; CS32582, a highly selective small-molecule allosteric inhibitor of tyrosine kinase 2; CS12088, a hepatitis B nucleocapsid assembly modulator; and CS12192 a highly selective JAK3 kinase inhibitor. The company was founded in 2001 and is headquartered in Shenzhen, China.